MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-11-2026
ProQR Therapeutics N.V. Market Cap 2011-2026 | PRQR
As of April 13, 2026 ProQR Therapeutics N.V. has a market cap of $ 99.5 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap ProQR Therapeutics N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 68.7 M | 188 M | 291 M | 454 M | 85 M | 96.9 M | 123 M | 223 M | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 454 M | 68.7 M | 191 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
62.9 B | $ 97.54 | 2.14 % | $ 27.2 B | Germany |
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 8.65 | 8.19 % | $ 85.5 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.63 | -2.42 % | $ 8.73 B |  Australia |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
561 M | $ 2.14 | -1.38 % | $ 445 M | USA |
 |
Evogene Ltd.
EVGN
|
66.3 M | $ 0.81 | -0.07 % | $ 27.9 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 20.47 | 0.49 % | $ 957 M | USA |
 |
Genmab A/S
GMAB
|
25 B | $ 28.2 | -0.18 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
8.42 B | $ 8.19 | -0.24 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
2.59 M | $ 0.36 | -2.82 % | $ 1.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Halozyme Therapeutics
HALO
|
9.66 B | $ 67.06 | -1.12 % | $ 8.04 B | USA |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.61 B | $ 28.69 | -0.69 % | $ 1.65 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 1.41 | 0.71 % | $ 363 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 2.96 | 1.37 % | $ 4.87 M | Israel |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 4.16 | 1.84 % | $ 445 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 24.01 | -0.85 % | $ 3.05 B | USA |
 |
ImmuCell Corporation
ICCC
|
58 M | $ 7.12 | 1.14 % | $ 64.3 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.04 B | $ 32.24 | - | $ 2.14 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.48 | -0.67 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
|
Immatics N.V.
IMTX
|
503 M | $ 10.48 | 0.43 % | $ 659 M | Germany |
 |
Cidara Therapeutics
CDTX
|
148 M | - | - | $ 1.41 B | USA |
 |
Incyte Corporation
INCY
|
19.5 B | $ 94.86 | -1.26 % | $ 18.5 B | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.61 | 2.35 % | $ 16.4 M | USA |
 |
InflaRx N.V.
IFRX
|
149 M | $ 1.05 | 4.5 % | $ 152 M | Germany |
 |
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | Britain |
 |
Inventiva S.A.
IVA
|
535 M | $ 5.18 | -1.52 % | $ 138 M | France |